CD82 anticorps (C-Term)

N° du produit ABIN1887018

Détail du produit anti-CD82 anticorps

Antigène: CD82

Épitope: C-Term

Reactivité: Humain, Souris, Rat

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp CD82 est non-conjugé

Application: Western Blotting (WB), ELISA, Immunohistochemistry (IHC)

Purification: Affinity chromatography purified via peptide column

Immunogène: 15 amino acid peptide from near the carboxy terminus of human KAI1.

Information d'application

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: PBS containing 0.02 % sodium azide.

Agent conservateur: Sodium azide

Précaution d'utilisation: WARNING: Reagents contain sodium azide. Sodium azide is very toxic if ingested or inhaled. Avoid contact with skin, eyes, or clothing. Wear eye or face protection when handling. If skin or eye contact occurs, wash with copious amounts of water. If ingested or inhaled, contact a physician immediately. Sodium azide yields toxic hydrazoic acid under acidic conditions. Dilute azide-containing compounds in running water before discarding to avoid accumulation of potentially explosive deposits in lead or copper plumbing.

Conseil sur la manipulation: Avoid freezing and thawing repeatly.

Stock: 4 °C/-20 °C

Stockage commentaire: Store at 4 °C for short term use.Store at -20 °C for long term preservation.

Détails sur CD82

Antigène: CD82

Autre désignation: KAI1 (CD82 Produits)

Synonymes: anticorps AA682076, anticorps AL023070, anticorps C33, anticorps IA4, anticorps Kai1, anticorps Tspan27, anticorps 4F9, anticorps GR15, anticorps KAI1, anticorps R2, anticorps SAR2, anticorps ST6, anticorps TSPAN27, anticorps CD82 antigen, anticorps CD82 molecule, anticorps Cd82 molecule, anticorps Cd82, anticorps CD82

Sujet: KAI1 was initially identified from a T-cell activation study as a four-transmembrane protein that plays an accessory role in T-cell activation, and was later determined to act as a cancer metastasis suppressor gene.This protein is ubiquitously expressed at moderate to high levels in most tissues, but its expression is downregulated during tumor progression.The loss of KAI1 and p53 is associated with poor survival for prostate and other cancer patients.Recently, KAI1 was found to interact with DARC, the Duffy antigen for chemokines using a yeast two hybrid screen.It is thought that tumor cells dislodged from the primary tumor and expressing KAI1 interact with DARC proteins expressed on vascular cells, transmitting a senescent signal to the tumor cells, while tumor cells that have lost KAI1 expression can proliferate and potentially give rise to metastases.At least two isoforms of KAI1 are known to exist.
Synonyms: CD82 antigen, tetraspanin-27, Tspan-27, suppressor of tumorgenicity-6

NCBI Accession: NP_002222

Pathways: Signalisation p53